Re: Zenith Epigentics and Resverlogix update 22 Jan 2018

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

tada

Rank: President [?]

Points: 7750 [?]

Votes: 40 Score: 3.4 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Epigentics and Resverlogix update 22 Jan 2018

in response to

Re: Zenith Epigentics and Resverlogix update 22 Jan 2018

SanFrancisco99

posted on Feb 01, 2018 12:04PM

SF - I contacted the person who sent this to me. In a round about way the response was that the company is now in a competative situation and does not want to put out any more information than they did so as to keep the advantage they believe they have.